{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:06:08Z","timestamp":1778544368560,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12325-025-03143-5","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T02:08:37Z","timestamp":1740967717000},"page":"1979-1993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin Lymphoma"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-5182","authenticated-orcid":false,"given":"Madeline","family":"Richey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Fullerton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7850-6701","authenticated-orcid":false,"given":"Qianyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tori","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-0390","authenticated-orcid":false,"given":"Hannah C.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Dolor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niquelle","family":"Wad\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-4966","authenticated-orcid":false,"given":"Kelly","family":"Magee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"3143_CR1","unstructured":"US Food and Drug Administration. Framework for FDA\u2019s Real-World Evidence Program. https:\/\/www.fda.gov\/media\/120060\/download. Accessed Jun 10, 2024."},{"issue":"1","key":"3143_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpt.2479","volume":"111","author":"P Arlett","year":"2022","unstructured":"Arlett P, Kj\u00e6r J, Broich K, Cooke E. Real-world evidence in EU medicines regulation: enabling use and establishing value. Clin Pharmacol Ther. 2022;111(1):21\u20133. https:\/\/doi.org\/10.1002\/cpt.2479.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3143_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","volume":"380","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018;380(1):45\u201356. https:\/\/doi.org\/10.1056\/nejmoa1804980.","journal-title":"N Engl J Med"},{"issue":"16","key":"3143_CR4","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138. https:\/\/doi.org\/10.1182\/blood-2017-03-769620.","journal-title":"Blood"},{"key":"3143_CR5","unstructured":"US Food and Drug Administration. BLINCYTO\u00ae (blinatumomab) for Minimal Residual Disease Positive (MRD+) B-cell Precursor Acute Lymphoblastic Leukemia (ALL). 2018. https:\/\/www.fda.gov\/media\/112191\/download. Accessed Jun 6, 2024."},{"issue":"8","key":"3143_CR6","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1007\/s12325-019-00970-1","volume":"36","author":"SD Griffith","year":"2019","unstructured":"Griffith SD, Tucker M, Bowser B, et al. Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer. Adv Ther. 2019;36(8):2122\u201336. https:\/\/doi.org\/10.1007\/s12325-019-00970-1.","journal-title":"Adv Ther"},{"issue":"3","key":"3143_CR7","doi-asserted-by":"publisher","first-page":"CCI.19.00013","DOI":"10.1200\/cci.19.00013","volume":"3","author":"SD Griffith","year":"2019","unstructured":"Griffith SD, Miksad RA, Calkins G, et al. Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non-small-cell lung cancer data set. JCO Clin Cancer Inform. 2019;3(3):CCI.19.00013. https:\/\/doi.org\/10.1200\/cci.19.00013.","journal-title":"JCO Clin Cancer Inform"},{"issue":"6","key":"3143_CR8","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1007\/s12325-022-02091-8","volume":"39","author":"AZ Torres","year":"2022","unstructured":"Torres AZ, Nussbaum NC, Parrinello CM, et al. Analysis of a real-world progression variable and related endpoints for patients with five different cancer types. Adv Ther. 2022;39(6):2831\u201349. https:\/\/doi.org\/10.1007\/s12325-022-02091-8.","journal-title":"Adv Ther"},{"issue":"27","key":"3143_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201367. https:\/\/doi.org\/10.1200\/jco.2013.54.8800.","journal-title":"J Clin Oncol"},{"key":"3143_CR10","unstructured":"US Food and Drug Administration. Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure | FDA. February 28, 2022. https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure. Accessed Jun 6, 2024."},{"issue":"10","key":"3143_CR11","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41375-020-0963-1","volume":"34","author":"J Zhu","year":"2020","unstructured":"Zhu J, Yang Y, Tao J, et al. Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. Leukemia. 2020;34(10):2576\u201391. https:\/\/doi.org\/10.1038\/s41375-020-0963-1.","journal-title":"Leukemia"},{"issue":"6","key":"3143_CR12","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/annonc\/mdq615","volume":"22","author":"L Lee","year":"2011","unstructured":"Lee L, Wang L, Crump M. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin\u2019s lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol. 2011;22(6):1392\u2013403. https:\/\/doi.org\/10.1093\/annonc\/mdq615.","journal-title":"Ann Oncol"},{"issue":"8","key":"3143_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/cci.23.00046","volume":"8","author":"EH Castellanos","year":"2024","unstructured":"Castellanos EH, Wittmershaus BK, Chandwani S. Raising the bar for real-world data in oncology: approaches to quality across multiple dimensions. JCO Clin Cancer Inform. 2024;8(8):e2300046. https:\/\/doi.org\/10.1200\/cci.23.00046.","journal-title":"JCO Clin Cancer Inform"},{"key":"3143_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.16.20037143","author":"X Ma","year":"2020","unstructured":"Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health SEER and NPCR. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.16.20037143.","journal-title":"medRxiv"},{"key":"3143_CR15","doi-asserted-by":"publisher","DOI":"10.48550\/arxiv.2001.09765","author":"B Birnbaum","year":"2020","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv. 2020. https:\/\/doi.org\/10.48550\/arxiv.2001.09765.","journal-title":"arXiv"},{"issue":"6","key":"3143_CR16","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1111\/1475-6773.12872","volume":"53","author":"MD Curtis","year":"2018","unstructured":"Curtis MD, Griffith SD, Tucker M, et al. Development and validation of a high-quality composite real-world mortality endpoint. Heal Serv Res. 2018;53(6):4460\u201376. https:\/\/doi.org\/10.1111\/1475-6773.12872.","journal-title":"Heal Serv Res"},{"key":"3143_CR17","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) B-Cell Lymphomas Version 3.2024. https:\/\/www.nccn.org. Accessed Oct 10, 2024."},{"key":"3143_CR18","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2147\/ott.s326632","volume":"15","author":"P Vodicka","year":"2022","unstructured":"Vodicka P, Klener P, Trneny M. Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options. OncoTargets Ther. 2022;15:1481\u2013501. https:\/\/doi.org\/10.2147\/ott.s326632.","journal-title":"OncoTargets Ther"},{"issue":"1","key":"3143_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2021.278766","volume":"107","author":"G Cartron","year":"2022","unstructured":"Cartron G, Trotman J. Time for an individualized approach to first-line management of follicular lymphoma. Haematologica. 2022;107(1):7\u201318. https:\/\/doi.org\/10.3324\/haematol.2021.278766.","journal-title":"Haematologica"},{"issue":"6","key":"3143_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","volume":"9","author":"A Kumar","year":"2019","unstructured":"Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9(6):50. https:\/\/doi.org\/10.1038\/s41408-019-0209-5.","journal-title":"Blood Cancer J"},{"issue":"3","key":"3143_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1200\/jco.19.01294","volume":"38","author":"HC Kluin-Nelemans","year":"2020","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial. J Clin Oncol. 2020;38(3):248\u201356. https:\/\/doi.org\/10.1200\/jco.19.01294.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3143_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjh.17513","volume":"194","author":"A Rampotas","year":"2021","unstructured":"Rampotas A, Wilson MR, Lomas O, et al. Treatment patterns and outcomes of unfit and elderly patients with mantle cell lymphoma unfit for standard immunochemotherapy: a UK and Ireland analysis. Br J Haematol. 2021;194(2):365\u201377. https:\/\/doi.org\/10.1111\/bjh.17513.","journal-title":"Br J Haematol"},{"issue":"4","key":"3143_CR23","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/bloodadvances.2021005715","volume":"6","author":"A Castellino","year":"2022","unstructured":"Castellino A, Wang Y, Larson MC, et al. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Adv. 2022;6(4):1350\u201360. https:\/\/doi.org\/10.1182\/bloodadvances.2021005715.","journal-title":"Blood Adv"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03143-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03143-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03143-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T07:09:24Z","timestamp":1742713764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03143-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3143"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03143-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time the study was conducted, Madeline Richey, Christina Fullerton, Qianyi Zhang, Tori Williams, Douglas Donnelly, Hannah C. Wise, Aaron Dolor, Niquelle Wad\u00e9, and Kelly Magee report employment at Flatiron Health, Inc., which is an independent member of the Roche Group, and stock ownership in Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. IRB approval of the study protocol, with a waiver of informed consent, was obtained before study conduct and covers the data from all sites represented. Approval was granted by the WCG IRB. (\u201cThe Flatiron Health Real-World Evidence Parent Protocol\u201d; IRB registration number IRB00000533; Protocol approval ID tracking number 420180044.)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}